Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00897442
Other study ID # GOG-0136
Secondary ID NCI-2009-00577GO
Status Completed
Phase N/A
First received May 9, 2009
Last updated October 26, 2016
Start date June 1992

Study information

Verified date October 2016
Source Gynecologic Oncology Group
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in the study of cancer.


Description:

PRIMARY OBJECTIVES:

I. To collect gynecologic tissue and blood from participating Gynecologic Oncology Group (GOG) institutions.

II. To provide a repository for long-term storage of gynecologic tissue and blood that will be used in studies designed to better understand the molecular biology of gynecologic tumors.

III. To make available, through the GOG Tissue Bank, tissue and blood for proposed projects conducted by GOG and non-GOG investigators.

OUTLINE:

Snap frozen tumor tissue, OCT molds of tumor tissue, formalin-preserved tumor tissue, buffy coat-prepared tumor tissue, and blood samples are collected and stored in the repository. Patient information is kept confidential, and patients are not informed of any research/test results from use of their tissues.


Recruitment information / eligibility

Status Completed
Enrollment 275
Est. completion date
Est. primary completion date January 2016
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- Any of the following:

- Patients who have had gynecologic tissue removed during surgery to diagnosis, treat, monitor, and/or prevent primary, persistent, or recurrent gynecologic cancer of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina, or vulva, meeting at least one of the following criteria:

- Group A: Women who underwent surgery, were diagnosed with a primary gynecologic malignancy of the ovary, cervix, uterine corpus, or vulva, and have primary tumor, normal tissue, and blood available for submission for this protocol

- Patients with ovarian cancer including all stages, grades, and common epithelial cell types

- Invasive cancers and serous and mucinous borderline tumors of low malignant potential are allowed

- At least 1 gram of frozen primary tumor tissue must be submitted for this protocol for patients with FIGO stage III or IV epithelial ovarian cancer

- Patients with an invasive malignancy of the cervix or uterine corpus including all stages, grades, and common cell types

- Patients with squamous cell carcinoma of the vulva

- Group B: Women who underwent surgery and were diagnosed with a rare gynecologic malignancy of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina, vulva, a gestational trophoblastic tumor, or a tumor arising in endometriosis, and have tumor tissue available for submission for this protocol

- Patients with a rare gynecologic malignancy of the ovary including malignant germ cell tumors; sex cord-stromal tumors; malignant mixed mesodermal tumors; clear cell, mucinous, small cell, or transitional cell carcinomas; malignant Brenner tumors; or borderline tumors of low malignant potential (except serous and mucinous)

- Patients with a rare gynecologic malignancy of the peritoneum, including primary peritoneal cancer or mesothelioma

- Patients with carcinoma of the fallopian tube

- Patients with a rare gynecologic malignancy of the cervix including verrucous, small cell, clear cell, serous, or adenoid cystic carcinomas; carcinoid tumors; malignant mixed mesodermal tumors; or leiomyosarcoma

- Patients with a rare gynecologic malignancy of the uterine corpus including leiomyosarcoma; malignant mixed mesodermal tumors; endometrial stromal sarcomas; smooth muscle tumors of unknown malignant potential; or clear cell or small cell carcinomas

- Patients with a rare gynecologic malignancy of the vagina including verrucous or clear cell carcinomas; melanoma; embryonal rhabdomyosarcoma; or endodermal sinus tumor

- Patients with a rare gynecologic malignancy of the vulva including verrucous carcinoma; melanoma; aggressive angiomyxoma; sarcoma; malignant Paget's disease; or Bartholin gland carcinoma

- Patients with a gestational trophoblastic tumor

- Patients with a tumor arising in endometriosis

- Group C: Women who underwent prophylactic oophorectomy and have at least 1 gram of ovarian tissue and blood available for submission for this protocol

- Group D: Women who underwent surgery to monitor or treat a persistent or recurrent gynecologic malignancy of the ovary, peritoneum, fallopian tube, cervix, uterine corpus, vagina, or vulva, and have persistent or recurrent tumor, normal tissue, and blood available for submission for this protocol

- Concurrent primary cancers are allowed

- No benign cystic tumors of the ovary, including cystic epithelial tumors and mature cystic teratomas

- Prior cytotoxic chemotherapy allowed

- Prior hormonal therapy allowed

- Prior radiotherapy allowed

- Prior surgery allowed

- No more than 6 weeks after prior surgery

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms

  • Adenocarcinoma
  • Borderline Ovarian Clear Cell Tumor
  • Borderline Ovarian Serous Tumor
  • Brenner Tumor
  • Carcinoma
  • Carcinoma, Adenosquamous
  • Carcinoma, Small Cell
  • Carcinoma, Squamous Cell
  • Cervical Adenocarcinoma
  • Cervical Adenosquamous Carcinoma
  • Cervical Small Cell Carcinoma
  • Cervical Squamous Cell Carcinoma, Not Otherwise Specified
  • Childhood Embryonal Rhabdomyosarcoma
  • Childhood Malignant Ovarian Germ Cell Tumor
  • Cystadenocarcinoma
  • Endometrioid Stromal Sarcoma
  • Fallopian Tube Neoplasms
  • Germinoma
  • Gestational Trophoblastic Disease
  • Gestational Trophoblastic Tumor
  • Leiomyosarcoma
  • Lung Neoplasms
  • Malignant Mesothelioma
  • Malignant Ovarian Epithelial Tumor
  • Melanoma
  • Mesothelioma
  • Neoplasm of Uncertain Malignant Potential
  • Neoplasms
  • Neoplasms, Germ Cell and Embryonal
  • Ovarian Brenner Tumor
  • Ovarian Clear Cell Cystadenocarcinoma
  • Ovarian Neoplasms
  • Ovarian Serous Cystadenocarcinoma
  • Paget Disease of the Vulva
  • Peritoneal Neoplasms
  • Recurrent Cervical Carcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Ovarian Germ Cell Tumor
  • Recurrent Primary Peritoneal Carcinoma
  • Recurrent Uterine Corpus Carcinoma
  • Recurrent Vaginal Carcinoma
  • Recurrent Vulvar Carcinoma
  • Rhabdomyosarcoma
  • Small Cell Lung Carcinoma
  • Stage I Ovarian Cancer
  • Stage I Uterine Corpus Cancer
  • Stage I Vaginal Cancer
  • Stage I Vulvar Cancer
  • Stage IA Cervical Cancer
  • Stage IA Fallopian Tube Cancer
  • Stage IA Ovarian Cancer
  • Stage IA Ovarian Germ Cell Tumor
  • Stage IB Cervical Cancer
  • Stage IB Fallopian Tube Cancer
  • Stage IB Ovarian Cancer
  • Stage IB Ovarian Germ Cell Tumor
  • Stage IC Fallopian Tube Cancer
  • Stage IC Ovarian Cancer
  • Stage IC Ovarian Germ Cell Tumor
  • Stage II Ovarian Cancer
  • Stage II Uterine Corpus Cancer
  • Stage II Vaginal Cancer
  • Stage II Vulvar Cancer
  • Stage IIA Cervical Cancer
  • Stage IIA Fallopian Tube Cancer
  • Stage IIA Ovarian Cancer
  • Stage IIA Ovarian Germ Cell Tumor
  • Stage IIB Cervical Cancer
  • Stage IIB Fallopian Tube Cancer
  • Stage IIB Ovarian Cancer
  • Stage IIB Ovarian Germ Cell Tumor
  • Stage IIC Fallopian Tube Cancer
  • Stage IIC Ovarian Cancer
  • Stage IIC Ovarian Germ Cell Tumor
  • Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor
  • Stage III Cervical Cancer
  • Stage III Uterine Corpus Cancer
  • Stage III Vaginal Cancer
  • Stage III Vulvar Cancer
  • Stage IIIA Fallopian Tube Cancer
  • Stage IIIA Ovarian Cancer
  • Stage IIIA Ovarian Germ Cell Tumor
  • Stage IIIA Primary Peritoneal Cancer
  • Stage IIIB Fallopian Tube Cancer
  • Stage IIIB Ovarian Cancer
  • Stage IIIB Ovarian Germ Cell Tumor
  • Stage IIIB Primary Peritoneal Cancer
  • Stage IIIC Fallopian Tube Cancer
  • Stage IIIC Ovarian Cancer
  • Stage IIIC Ovarian Germ Cell Tumor
  • Stage IIIC Primary Peritoneal Cancer
  • Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor
  • Stage IV Fallopian Tube Cancer
  • Stage IV Ovarian Cancer
  • Stage IV Primary Peritoneal Cancer
  • Stage IV Uterine Corpus Cancer
  • Stage IVA Cervical Cancer
  • Stage IVA Vaginal Cancer
  • Stage IVB Cervical Cancer
  • Stage IVB Vaginal Cancer
  • Stage IVB Vulvar Cancer
  • Trophoblastic Neoplasms
  • Uterine Cervical Neoplasms
  • Uterine Corpus Cancer
  • Uterine Corpus Leiomyosarcoma
  • Uterine Neoplasms
  • Vaginal Neoplasms
  • Vulvar Neoplasms
  • Vulvar Squamous Cell Carcinoma

Intervention

Other:
Laboratory Biomarker Analysis
Correlative studies

Locations

Country Name City State
United States Abington Memorial Hospital Abington Pennsylvania
United States Akron General Medical Center Akron Ohio
United States University of New Mexico Cancer Center Albuquerque New Mexico
United States Lehigh Valley Hospital-Cedar Crest Allentown Pennsylvania
United States The Don and Sybil Harrington Cancer Center Amarillo Texas
United States University of Michigan Comprehensive Cancer Center Ann Arbor Michigan
United States Our Lady Bellefonte Hospital Ashland Kentucky
United States Northside Hospital Atlanta Georgia
United States MultiCare Auburn Medical Center Auburn Washington
United States Augusta University Medical Center Augusta Georgia
United States Colorado Gynecologic Oncology Group Aurora Colorado
United States University of Colorado Cancer Center - Anschutz Cancer Pavilion Aurora Colorado
United States University Medical Center Brackenridge Austin Texas
United States MedStar Franklin Square Medical Center/Weinberg Cancer Institute Baltimore Maryland
United States The Union Memorial Hospital Baltimore Maryland
United States Woman's Hospital Baton Rouge Louisiana
United States Walter Reed National Military Medical Center Bethesda Maryland
United States Saint Luke's University Hospital-Bethlehem Campus Bethlehem Pennsylvania
United States Roswell Park Cancer Institute Buffalo New York
United States Providence Saint Joseph Medical Center/Disney Family Cancer Center Burbank California
United States Cooper Hospital University Medical Center Camden New Jersey
United States Providence Regional Cancer System-Centralia Centralia Washington
United States UNC Lineberger Comprehensive Cancer Center Chapel Hill North Carolina
United States Medical University of South Carolina Charleston South Carolina
United States Carolinas Medical Center/Levine Cancer Institute Charlotte North Carolina
United States Novant Health Presbyterian Medical Center Charlotte North Carolina
United States Chattanooga's Program in Women's Oncology Chattanooga Tennessee
United States Northwestern University Chicago Illinois
United States Rush University Medical Center Chicago Illinois
United States University of Illinois Chicago Illinois
United States Marshfield Clinic-Chippewa Center Chippewa Falls Wisconsin
United States Good Samaritan Hospital - Cincinnati Cincinnati Ohio
United States University of Cincinnati Cincinnati Ohio
United States Case Western Reserve University Cleveland Ohio
United States Medical Oncology and Hematology Associates-West Des Moines Clive Iowa
United States Mercy Cancer Center-West Lakes Clive Iowa
United States University of Missouri - Ellis Fischel Columbia Missouri
United States Ohio State University Comprehensive Cancer Center Columbus Ohio
United States Riverside Methodist Hospital Columbus Ohio
United States Clements University Hospital Dallas Texas
United States Parkland Memorial Hospital Dallas Texas
United States UT Southwestern/Simmons Cancer Center-Dallas Dallas Texas
United States Zale Lipshy University Hospital Dallas Texas
United States Danbury Hospital Danbury Connecticut
United States Geisinger Medical Center Danville Pennsylvania
United States Iowa Lutheran Hospital Des Moines Iowa
United States Iowa Methodist Medical Center Des Moines Iowa
United States Iowa-Wide Oncology Research Coalition NCORP Des Moines Iowa
United States Medical Oncology and Hematology Associates-Des Moines Des Moines Iowa
United States Medical Oncology and Hematology Associates-Laurel Des Moines Iowa
United States Mercy Medical Center - Des Moines Des Moines Iowa
United States Wayne State University/Karmanos Cancer Institute Detroit Michigan
United States Marshfield Clinic Cancer Center at Sacred Heart Eau Claire Wisconsin
United States Sacred Heart Hospital Eau Claire Wisconsin
United States Saint Elizabeth Medical Center South Edgewood Kentucky
United States Highlands Oncology Group PA - Fayetteville Fayetteville Arkansas
United States Washington Regional Medical Center - Fayetteville Fayetteville Arkansas
United States Saint Francis Hospital Federal Way Washington
United States Hurley Medical Center Flint Michigan
United States Holy Cross Hospital Fort Lauderdale Florida
United States Florida Gynecologic Oncology Fort Myers Florida
United States Brooke Army Medical Center Fort Sam Houston Texas
United States Northeast Georgia Medical Center Gainesville Georgia
United States University of Texas Medical Branch Galveston Texas
United States Gynecologic Oncology of West Michigan PLLC Grand Rapids Michigan
United States East Carolina University Greenville North Carolina
United States Greenville Health System Cancer Institute-Faris Greenville South Carolina
United States Gynecologic Oncology Network Greenville North Carolina
United States Pitt County Memorial Hosp Inc. Greenville North Carolina
United States Hackensack University Medical CCOP Hackensack New Jersey
United States Hackensack University Medical Center Hackensack New Jersey
United States Virginia Oncology Associates-Hampton Hampton Virginia
United States Hartford Hospital Hartford Connecticut
United States The Methodist Hospital System Houston Texas
United States Indiana University/Melvin and Bren Simon Cancer Center Indianapolis Indiana
United States Saint Vincent Hospital and Health Care Center Indianapolis Indiana
United States University of Iowa/Holden Comprehensive Cancer Center Iowa City Iowa
United States Saint Dominic-Jackson Memorial Hospital Jackson Mississippi
United States University of Mississippi Medical Center Jackson Mississippi
United States East Tennessee State University Johnson City Tennessee
United States Jupiter Medical Center Jupiter Florida
United States Keesler Medical Center Kessler AFB Mississippi
United States Southeast Gynecologic Oncology Associates Knoxville Tennessee
United States Wilford Hall Medical Center Lackland AFB Texas
United States Marshfield Clinic - Ladysmith Center Ladysmith Wisconsin
United States Saint Clare Hospital Lakewood Washington
United States Sunrise Hospital and Medical Center Las Vegas Nevada
United States Women's Cancer Center of Nevada Las Vegas Nevada
United States Dartmouth Hitchcock Medical Center Lebanon New Hampshire
United States University of Kentucky/Markey Cancer Center Lexington Kentucky
United States University of Arkansas for Medical Sciences Little Rock Arkansas
United States Long Beach Memorial Medical Center-Todd Cancer Institute Long Beach California
United States UCLA / Jonsson Comprehensive Cancer Center Los Angeles California
United States Norton Hospital Pavilion and Medical Campus Louisville Kentucky
United States Covenant Medical Center-Lakeside Lubbock Texas
United States Texas Tech University Health Sciences Center Lubbock Texas
United States University of Wisconsin Hospital and Clinics Madison Wisconsin
United States Marshfield Clinic Marshfield Wisconsin
United States Saint Joseph's Hospital Marshfield Wisconsin
United States University of Tennessee Health Science Center Memphis Tennessee
United States Lake University Ireland Cancer Center Mentor Ohio
United States University of Miami Miller School of Medicine-Sylvester Cancer Center Miami Florida
United States Aurora Saint Luke's Medical Center Milwaukee Wisconsin
United States Aurora Sinai Medical Center Milwaukee Wisconsin
United States Froedtert and the Medical College of Wisconsin Milwaukee Wisconsin
United States Winthrop University Hospital Mineola New York
United States University of Minnesota/Masonic Cancer Center Minneapolis Minnesota
United States Marshfield Clinic-Minocqua Center Minocqua Wisconsin
United States Meharry Medical College Nashville Tennessee
United States Vanderbilt University/Ingram Cancer Center Nashville Tennessee
United States The Hospital of Central Connecticut New Britain Connecticut
United States Yale University New Haven Connecticut
United States Tulane University Health Sciences Center New Orleans Louisiana
United States Columbia University/Herbert Irving Cancer Center New York New York
United States Mount Sinai Medical Center New York New York
United States Rutgers New Jersey Medical School Newark New Jersey
United States Advocate Christ Medical Center Oak Lawn Illinois
United States University of Oklahoma Health Sciences Center Oklahoma City Oklahoma
United States Capital Medical Center Olympia Washington
United States Providence - Saint Peter Hospital Olympia Washington
United States Nebraska Methodist Hospital Omaha Nebraska
United States UC Irvine Health/Chao Family Comprehensive Cancer Center Orange California
United States Stanford Cancer Institute Palo Alto California
United States Fox Chase Cancer Center Philadelphia Pennsylvania
United States Temple University Hospital Philadelphia Pennsylvania
United States FirstHealth of the Carolinas-Moore Regional Hosiptal Pinehurst North Carolina
United States UPMC-Magee Womens Hospital Pittsburgh Pennsylvania
United States West Penn Hospital Pittsburgh Pennsylvania
United States Compass Oncology Rose Quarter Portland Oregon
United States Legacy Good Samaritan Hospital and Medical Center Portland Oregon
United States Maine Medical Center-Bramhall Campus Portland Maine
United States Women and Infants Hospital Providence Rhode Island
United States MultiCare Good Samaritan Hospital Puyallup Washington
United States Black Hills Obstetrics and Gynecology Rapid City South Dakota
United States Marshfield Clinic at James Beck Cancer Center Rhinelander Wisconsin
United States Marshfield Clinic-Rice Lake Center Rice Lake Wisconsin
United States Carilion Clinic Gynecological Oncology Roanoke Virginia
United States University of California Davis Comprehensive Cancer Center Sacramento California
United States Saint Louis University Hospital Saint Louis Missouri
United States Washington University School of Medicine Saint Louis Missouri
United States UCSF Medical Center-Mount Zion San Francisco California
United States Memorial University Medical Center Savannah Georgia
United States Fred Hutchinson Cancer Research Center Seattle Washington
United States Pacific Gynecology Specialists Seattle Washington
United States Seattle Cancer Care Alliance Seattle Washington
United States Swedish Medical Center-First Hill Seattle Washington
United States University of Washington Medical Center Seattle Washington
United States Virginia Mason CCOP Seattle Washington
United States Virginia Mason Medical Center Seattle Washington
United States CHRISTUS Highland Medical Center Shreveport Louisiana
United States Avera Cancer Institute Sioux Falls South Dakota
United States Sanford Cancer Center-Oncology Clinic Sioux Falls South Dakota
United States Sanford USD Medical Center - Sioux Falls Sioux Falls South Dakota
United States Northern Indiana Cancer Research Consortium South Bend Indiana
United States Greenville Health System Cancer Institute-Spartanburg Spartanburg South Carolina
United States Baystate Medical Center Springfield Massachusetts
United States Cancer Research for the Ozarks NCORP Springfield Missouri
United States CoxHealth South Hospital Springfield Missouri
United States Memorial Medical Center Springfield Illinois
United States Mercy Hospital Springfield Springfield Missouri
United States Geisinger Medical Group State College Pennsylvania
United States Marshfield Clinic Cancer Care at Saint Michael's Hospital Stevens Point Wisconsin
United States Saint Michael's Hospital Stevens Point Wisconsin
United States Stony Brook University Medical Center Stony Brook New York
United States Olive View-University of California Los Angeles Medical Center Sylmar California
United States MultiCare Allenmore Hospital Tacoma Washington
United States Multicare Health System Tacoma Washington
United States MultiCare Tacoma General Hospital Tacoma Washington
United States Northwest Medical Specialties PLLC Tacoma Washington
United States Northwest NCI Community Oncology Research Program Tacoma Washington
United States Saint Joseph Medical Center Tacoma Washington
United States Scott and White Memorial Hospital Temple Texas
United States Cancer Care Associates-Midtown Tulsa Oklahoma
United States Oklahoma Cancer Specialists and Research Institute-Tulsa Tulsa Oklahoma
United States MedStar Washington Hospital Center Washington District of Columbia
United States Sibley Memorial Hospital Washington District of Columbia
United States Marshfield Clinic-Wausau Center Wausau Wisconsin
United States Aurora West Allis Medical Center West Allis Wisconsin
United States Mercy Medical Center-West Lakes West Des Moines Iowa
United States Methodist West Hospital West Des Moines Iowa
United States Diagnostic and Treatment Center Weston Wisconsin
United States Marshfield Clinic - Weston Center Weston Wisconsin
United States Geisinger Wyoming Valley/Henry Cancer Center Wilkes-Barre Pennsylvania
United States Wake Forest University Health Sciences Winston-Salem North Carolina
United States Marshfield Clinic - Wisconsin Rapids Center Wisconsin Rapids Wisconsin
United States University of Massachusetts Medical School Worcester Massachusetts
United States University of Massachusetts Memorial Health Care Worcester Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Gynecologic Oncology Group National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Collection of gynecological tumor specimens and serum from patients at GOG institutions Baseline No
Primary Create a repository for long-term storage of these specimens Baseline No
Primary Make available tissue and blood for proposed projects Baseline No
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study
Completed NCT00297895 - Multicenter Selective Lymphadenectomy Trial II (MSLT-II) N/A